Published in J Am Heart Assoc on January 13, 2016
Cardiovascular Effects of Selective I(f)-Channel Blockade | NCT00865917
Chronic Treatment with Ivabradine Does Not Affect Cardiovascular Autonomic Control in Rats. Front Physiol (2016) 0.75
The two-period cross-over clinical trial. Br J Clin Pharmacol (1979) 13.21
Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet (2010) 8.17
Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med (2014) 5.41
Mechanism of frequency-dependent inhibition of sodium currents in frog myelinated nerve by the lidocaine derivative GEA. J Pharmacol Exp Ther (1975) 5.07
How does adrenaline accelerate the heart? Nature (1979) 3.54
The neuropathic postural tachycardia syndrome. N Engl J Med (2000) 2.86
Familial sinus bradycardia associated with a mutation in the cardiac pacemaker channel. N Engl J Med (2006) 2.69
Adverse consequences of high sympathetic nervous activity in the failing human heart. J Am Coll Cardiol (1995) 2.15
Pacemaker channel dysfunction in a patient with sinus node disease. J Clin Invest (2003) 2.14
HCN4 provides a 'depolarization reserve' and is not required for heart rate acceleration in mice. EMBO J (2007) 2.13
Molecular characterization of a slowly gating human hyperpolarization-activated channel predominantly expressed in thalamus, heart, and testis. Proc Natl Acad Sci U S A (1999) 2.07
Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. Circulation (2003) 1.86
Heart rate lowering by specific and selective I(f) current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease. Drugs (2004) 1.85
Functional characterization of a trafficking-defective HCN4 mutation, D553N, associated with cardiac arrhythmia. J Biol Chem (2004) 1.75
Muscarinic control of the hyperpolarization-activated current (if) in rabbit sino-atrial node myocytes. J Physiol (1988) 1.71
Single centre experience of ivabradine in postural orthostatic tachycardia syndrome. Europace (2010) 1.65
Chronic orthostatic intolerance: a disorder with discordant cardiac and vascular sympathetic control. Circulation (1998) 1.64
Influence of sibutramine treatment on sympathetic vasomotor tone in obese subjects. Clin Pharmacol Ther (2006) 1.59
Point mutation in the HCN4 cardiac ion channel pore affecting synthesis, trafficking, and functional expression is associated with familial asymptomatic sinus bradycardia. Circulation (2007) 1.55
Current-dependent block of rabbit sino-atrial node I(f) channels by ivabradine. J Gen Physiol (2002) 1.52
Chronic atrial fibrillation alters the functional properties of If in the human atrium. J Cardiovasc Electrophysiol (2013) 1.48
Cardiac pacemaker function of HCN4 channels in mice is confined to embryonic development and requires cyclic AMP. EMBO J (2008) 1.47
Differential distribution and function of hyperpolarization-activated channels in sensory neurons and mechanosensitive fibers. J Neurosci (2004) 1.26
Selective impairment in sympathetic vasomotor control with norepinephrine transporter inhibition. Circulation (2003) 1.01
Altered HCN4 channel C-linker interaction is associated with familial tachycardia-bradycardia syndrome and atrial fibrillation. Eur Heart J (2012) 1.01
Cardiac pacemaker I(f) current and its inhibition by heart rate-reducing agents. Curr Med Res Opin (2005) 1.00
Pharmacokinetic-pharmacodynamic modeling of the effects of ivabradine, a direct sinus node inhibitor, on heart rate in healthy volunteers. Clin Pharmacol Ther (1998) 0.97
Baroreflex buffering and susceptibility to vasoactive drugs. Circulation (2002) 0.94
Increased cardiac sympathetic nervous activity in patients with unstable coronary heart disease. Eur Heart J (1993) 0.91
Blunted excitability of aortic baroreceptor neurons in diabetic rats: involvement of hyperpolarization-activated channel. Cardiovasc Res (2008) 0.90
Pacemaker current inhibition in experimental human cardiac sympathetic activation: a double-blind, randomized, crossover study. Clin Pharmacol Ther (2014) 0.86
Identification of the molecular site of ivabradine binding to HCN4 channels. PLoS One (2013) 0.86
HCN4 subunit expression in fast-spiking interneurons of the rat spinal cord and hippocampus. Neuroscience (2013) 0.84
Numerical Modeling Calcium and CaMKII Effects in the SA Node. Front Pharmacol (2014) 0.84
Stability of plasma free metanephrines during collection and storage as assessed by an optimized HPLC method with electrochemical detection. Clin Chem (2003) 0.83
Roles of hyperpolarization-activated current If in sinoatrial node pacemaking: insights from bifurcation analysis of mathematical models. Am J Physiol Heart Circ Physiol (2010) 0.83
Alpha-2 adrenergic transmission and human baroreflex regulation. Hypertension (2004) 0.82
Pharmacokinetic and safety profile of ivabradine in healthy Chinese men: a phase I, randomized, open-label, increasing single- and multiple-dose study. Clin Ther (2013) 0.81
A novel pharmacological approach to determining parasympathetic heart rate reserve in human subjects. Clin Pharmacol Ther (2010) 0.77
[Effect of the I(f) channel blocker ivabradine on the parameters of external respiration function in patients with chronic obstructive pulmonary disease in its stable course period]. Ter Arkh (2010) 0.76
Patients with continuous-flow left ventricular assist devices provide insight in human baroreflex physiology. Hypertension (2012) 0.76